MoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on Wednesday

Key Points

• MoonLake Immunotherapeutics is set to release its Q1 2025 earnings report on August 6th, with analysts predicting a loss of ($0.73) per share.
• The company's previous earnings report in May showed a loss of ($0.63) per share, which exceeded analysts' estimates of ($0.76) per share.
• Several research firms have assigned an "outperform" rating to MoonLake Immunotherapeutics, with price targets ranging from $61.00 to $80.00.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, August 6th. Analysts expect MoonLake Immunotherapeutics to post earnings of ($0.73) per share for the quarter.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.13. During the same period in the prior year, the firm earned ($0.22) earnings per share. On average, analysts expect MoonLake Immunotherapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MoonLake Immunotherapeutics Trading Up 4.9%

NASDAQ MLTX traded up $2.48 during trading on Friday, reaching $52.92. 957,582 shares of the stock traded hands, compared to its average volume of 486,550. MoonLake Immunotherapeutics has a fifty-two week low of $31.42 and a fifty-two week high of $58.26. The company has a quick ratio of 21.11, a current ratio of 21.11 and a debt-to-equity ratio of 0.18. The firm has a market cap of $3.39 billion, a price-to-earnings ratio of -23.01 and a beta of 1.27. The stock's 50-day moving average price is $46.95 and its 200 day moving average price is $42.77.

Institutional Trading of MoonLake Immunotherapeutics

An institutional investor recently raised its position in MoonLake Immunotherapeutics stock. Millennium Management LLC grew its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 3,343.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 344,320 shares of the company's stock after purchasing an additional 334,320 shares during the quarter. Millennium Management LLC owned approximately 0.54% of MoonLake Immunotherapeutics worth $13,453,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 93.85% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Wolfe Research raised MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 target price for the company in a research note on Monday, May 19th. Needham & Company LLC reissued a "buy" rating and set a $66.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Redburn Atlantic raised shares of MoonLake Immunotherapeutics to a "hold" rating in a research note on Monday. Wedbush reiterated an "outperform" rating and issued a $80.00 price target (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Finally, Rothschild & Co Redburn initiated coverage on shares of MoonLake Immunotherapeutics in a research report on Monday. They issued a "neutral" rating and a $65.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $73.14.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.